Home
EN / FR

Celyad Oncology

Home

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev-1

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

June 11, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

May 31, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces June 2021 Conference Schedule

May 26, 2021
READ THE PRESS RELEASE

Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

May 19, 2021
READ THE PRESS RELEASE

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

May 12, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

May 6, 2021
READ THE PRESS RELEASE

Transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

May 5, 2021
READ THE PRESS RELEASE

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

May 4, 2021
READ THE PRESS RELEASE

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

April 19, 2021
READ THE PRESS RELEASE

Celyad Oncology Announces April 2021 Conference Schedule

April 1, 2021
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres-1

Celyad Oncology@CelyadSA·
22h

#CancerImmunotherapy, also known as #ImmunoOncology, is a form of #CancerTreatment that uses the power of the body’s own #ImmuneSystem to prevent, control, & eliminate cancer. Immunotherapy can boost immune cells to help them eliminate cancer, & much more: https://buff.ly/36SAdDV

Celyad Oncology@CelyadSA·
11 Jun

Earlier this morning, we presented an important update and the latest data from the Phase 1 IMMUNICY-1 #clinicaltrial evaluating one of our #allogeneic CAR T candidates, CYAD-211. Read the full PR and discover our data by clicking here: https://buff.ly/357EVLV

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.